impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Differences between familial and sporadic early spondyloarthritis: results from the ESPERANZA cohort

1, 2, 3, 4, 5, 6

 

  1. Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain. ralmodovar@fhalcorcon.es
  2. Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain.
  3. Rheumatology Unit, Hospital Universitario de Elda, Alicante, Spain.
  4. Rheumatology Unit, Hospital Universitario Virgen de la Salud, Toledo, Spain.
  5. Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain.
  6. Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

and the ESPERANZA Study Group

CER8554
2016 Vol.34, N°4
PI 0575, PF 0580
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27384500 [PubMed]

Received: 21/04/2015
Accepted : 02/11/2015
In Press: 22/06/2016
Published: 14/07/2016

Abstract

OBJECTIVES:
To describe and evaluate clinical and imaging differences between patients with familial and sporadic early spondyloarthritis (SpA).
METHODS:
This was a cross-sectional study analysing the baseline dataset from ESPERANZA, a national programme developed for the early identification of patients with SpA. Patients fulfilling SpA ASAS classification criteria were included. Familial SpA was defined according to the ASAS/ESSG criteria as the presence in first- or second-degree relatives of any of the following: ankylosing spondylitis, psoriasis, uveitis, reactive arthritis, and inflammatory bowel disease. Socio-demographic and disease characteristics, disease activity, metrology and laboratory and imaging data were compared by descriptive and bivariate statistics.
RESULTS:
A total of 377 patients were included - 64% men, mean age 32, and mean disease duration 12 months. Out of these, 132 (35%) patients (101 axial and 31 peripheral SpA) were familial forms. In patients with axial SpA, statistically significant differences (p<0.05) were found between familial and sporadic forms regarding age at symptoms onset (29.4±9.2 vs. 31.5±10 years), HLA B27 positivity (83% vs. 71%), BASMI (1.2± 13 vs. 1.6 1.2) and sacroiliitis on magnetic resonance imaging (36% vs. 47%), respectively. In patients with peripheral SpA, there were no significant differences for any of the variables analysed.
CONCLUSIONS:
Familial axial SpA presents symptoms at a younger age, is more frequently HLA-B27 positive and shows better spinal mobility than sporadic axial SpA; this latter presenting sacroiliitis on MRI more frequently than familial axial SpA. Apparently, no differences exist in the expression of familial or sporadic peripheral SpA.

Rheumatology Article